Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cancer is becoming more of a chronic disease due to improvements in treatment and early detection for multiple cancer sites. To gain insight on increased life expectancy due to these improvements, we quantified trends in the loss in expectation of life (LEL) due to a cancer diagnosis for six cancer sites from 1975 through 2018.
Methods: We focused on patients diagnosed with female breast cancer, chronic myeloid leukemia (CML), colon and rectum cancer, diffuse large B-cell lymphoma (DLBCL), lung cancer, or melanoma between 1975 and 2018 from nine Surveillance, Epidemiology, and End Results cancer registries. Life expectancies for patients with cancer ages 50+ were modeled using flexible parametric survival models. LEL was calculated as the difference between general population life expectancy and life expectancy for patients with cancer.
Results: Over 2 million patients were diagnosed with one of the six cancers between 1975 and 2018. Large increases in life expectancy were observed between 1990 and 2010 for female breast, DLBCL, and CML. Patients with colon and rectum cancer and melanoma had more gradual improvements in life expectancy. Lung cancer LEL only began decreasing after 2005. Increases in life expectancy corresponded with decreases in LEL for patients with cancer.
Conclusions: The reported gains in life expectancy largely correspond to progress in the screening, management, and treatment of these six cancers since 1975.
Impact: LEL provides an important public health perspective on how improvements in treatment and early detection and their impacts on survival translate into changes in cancer patients' life expectancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10872878 | PMC |
| http://dx.doi.org/10.1158/1055-9965.EPI-23-1006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis.
BMJ Open
September 2025
Genentech, South San Francisco, California, USA.
Objectives: Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how health effects and costs from funding an intervention are distributed among population subgroups. The objective was to evaluate how funding emicizumab for people with severe haemophilia A (PwSHA) impacts population health and health disparities in the USA.
View Article and Find Full Text PDFTherapeutic Acute Intermittent Hypoxia Modestly Improves Breathing in Pompe Disease.
Respir Physiol Neurobiol
September 2025
Department of Pediatrics, School of Medicine, Duke University.
Pompe disease is an autosomal recessive neuromuscular disorder characterized by a deficiency of acid α-glucosidase (GAA), an enzyme responsible for lysosomal glycogen degradation in all cells. Respiratory distress is a common symptom among patients with Pompe disease resulting from weakness of primary respiratory neuromuscular units of the diaphragm and genioglossus and the motor neurons which innervate them. The only FDA approved treatment is enzyme replacement therapy (ERT) of recombinant human GAA (rhGAA) which slows the decline of motor function and extends life expectancy.
View Article and Find Full Text PDFWhat Not to Miss in Fetal Head and Neck MRI: A Pictorial Essay.
Semin Ultrasound CT MR
September 2025
Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address:
Fetal magnetic resonance imaging (MRI) is a safe method of in-utero evaluation of fetal anomalies and a valuable adjunct to prenatal ultrasound. The utilization of rapid sequences reduces the impact of fetal motion and allows for high contrast resolution of fetal structures. A thorough understanding of fetal anatomy and a systematic approach to MRI interpretation are essential for accurate diagnosis of fetal head and neck anomalies.
View Article and Find Full Text PDFMortality and potential years of life lost due to COVID-19 among healthcare workers in Bahia, 2020-2022.
Epidemiol Serv Saude
September 2025
Universidade Federal da Bahia, Programa de Pós-Graduação em Saúde, Ambiente e Trabalho, Salvador, BA, Brazil.
Objective: Estimate mortality indicators and impact of COVID-19 on healthcare workers in Bahia in the period 2020-2022.
Methods: This is a descriptive study, with death data extracted from the Brazilian Mortality Information System. Population data were obtained from professional councils, the National Registry of Health Establishments and the Brazilian National Immunization Program Information System.
Global, regional, and national burdens of five main digestive system cancers in adolescents and young adults from 1990 to 2021 based on the Global Burden of Disease Study 2021: A cross-sectional study.
PLoS One
September 2025
Department of Gastroenterology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, China.
Objective: To evaluate the burden and trends of digestive system cancers in adolescents and young adults (AYAs) globally between 1990 and 2021.
Methods: Data were extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (1990-2021). We analyzed global, regional, and national disease burdens by calculating the age-standardized incidence (ASIR), mortality (ASMR), and disability-adjusted life years (DALYs) for AYAs.